Results 51 to 60 of about 5,458 (150)

Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study

Cancer, Volume 130, Issue 16, Page 2812-2821, 15 August 2024.
Abstract Introduction Nirogacestat is a targeted gamma secretase inhibitor approved in the United States for adults with progressing desmoid tumors. In the phase 3 DeFi study (NCT03785964) of nirogacestat, ovarian toxicity (OT) was identified as a safety signal among females of reproductive potential (FORP).
Elizabeth T. Loggers, Rashmi Chugh, Noah Federman, Lee Hartner, Richard F. Riedel, Sunny Cho, David Hyslop, Allison Lim, Ana B. Oton, Kutluk H. Oktay   +9 more
wiley   +1 more source

LAS: a software platform to support oncological data management [PDF]

, 2012
The rapid technological evolution in the biomedical and molecular oncology fields is providing research laboratories with huge amounts of complex and heterogeneous data.
A El Akadi, A Tolopko, Alberto Grand, Alessandro Fiori, Andrea Bertotti, Elena Baralis, H Maier, J Wang, K Kuhn, S Clément, S Haquin, TR Golub   +11 more
core   +1 more source

MEDINFO 2013

, 2013
Changing demographics, volatile economics and dwindling resources are among the factors contributing to the need for collective and collaborative efforts to address the new and evolving challenges in healthcare and biomedicine.This book presents the proceedings of the MEDINFO 2013 conference, held in Copenhagen, Denmark, in August 2013.
  +5 more sources

Формализация клинической информации для оптимизации лечебно-диагностического процесса в терапевтической практике [PDF]

, 2016
Предложенная технология формализации клинической информации позволяет решить отдельные вопросы, связанные с проблемой кореферентности (семантической совместимости электронных медицинских записей), что открывает возможность интегрирования различных данных
Кузьминов, О. М., Синица, И. В., Фетисова, В. И.   +2 more
core   +2 more sources

Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B‐cell lymphoma after 2 or more lines of prior therapy

American Journal of Hematology, Volume 99, Issue 5, Page 880-889, May 2024.
Abstract Axicabtagene ciloleucel (axi‐cel) in trials has demonstrated favorable efficacy compared with historical controls after ≥2 lines of therapy for the treatment of relapsed or refractory (R/R) large B cell lymphoma (LBCL). Herein, we compared the real‐world effectiveness of axi‐cel with efficacy and effectiveness of chemoimmunotherapy (CIT) in ...
Matthew A. Lunning, Hai‐lin Wang, Zhen‐Huan Hu, Frederick L. Locke, Tanya Siddiqi, Caron A. Jacobson, Sairah Ahmed, David B. Miklos, Yi Lin, Brian T. Hill, Armin Ghobadi, Sattva S. Neelapu, Jason Westin, Christopher Dieyi, Polly Field, Harry Miao, Shilpa A. Shahani, Anik Patel, Clare Spooner, Christine Fu, David Muramoto, Hairong Xu, Marcelo C. Pasquini   +22 more
wiley   +1 more source

Knowledge-based best of breed approach for automated detection of clinical events based on German free text digital hospital discharge letters [PDF]

, 2019
OBJECTIVES: The secondary use of medical data contained in electronic medical records, such as hospital discharge letters, is a valuable resource for the improvement of clinical care (e.g. in terms of medication safety) or for research purposes. However,
Demuth, Ilja, Diekmann, Daniel, König, Maximilian, Sander, André, Steinhagen-Thiessen, Elisabeth   +4 more
core   +1 more source

Nature‐versus‐nurture considered harmful: Actionability as an alternative tool for understanding the exposome from an ethical perspective

Bioethics, Volume 38, Issue 4, Page 356-366, May 2024.
Abstract Exposome research is put forward as a major tool for solving the nature‐versus‐nurture debate because the exposome is said to represent “the nature of nurture.” Against this influential idea, we argue that the adoption of the nature‐versus‐nurture debate into the exposome research program is a mistake that needs to be undone to allow for a ...
Caspar W. Safarlou, Annelien L. Bredenoord, Roel Vermeulen, Karin R. Jongsma   +3 more
wiley   +1 more source

Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trial

Muscle &Nerve, Volume 69, Issue 1, Page 93-98, January 2024.
Abstract Introduction/Aims Delandistrogene moxeparvovec is indicated in the United States for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. Long‐term delandistrogene moxeparvovec microdystrophin protein (a shortened dystrophin that retains key ...
Jerry R. Mendell, Zarife Sahenk, Kelly J. Lehman, Linda P. Lowes, Natalie F. Reash, Megan A. Iammarino, Lindsay N. Alfano, Sarah Lewis, Kathleen Church, Richard Shell, Rachael A. Potter, Danielle A. Griffin, Mark Hogan, Shufang Wang, Stefanie Mason, Eddie Darton, Louise R. Rodino‐Klapac   +16 more
wiley   +1 more source

The Usefulness of Activity Trackers in Elderly with Reduced Mobility: A Case Study [PDF]

, 2013
This study was conducted to determine the accuracy and usefulness of two current commercially available activity trackers in rollator dependent elderly with reduced mobility (RME), compared with elderly with normal mobility (NME) and healthy adults ...
Civit Balcells, Antón, Lauritzen, Jonas, Muñoz Macho, Adolfo, Sevillano Ramos, José Luis   +3 more
core  

Biomedical ontology alignment: An approach based on representation learning [PDF]

, 2018
While representation learning techniques have shown great promise in application to a number of different NLP tasks, they have had little impact on the problem of ontology matching.
Kalousis, Alexandros, Kiritsis, Dimitris, Kolyvakis, Prodromos, Smith, Barry   +3 more
core   +1 more source